Tempest Therapeutics Other Stockholder Equity Over Time
| TPST Stock | USD 1.10 0.01 0.92% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Tempest Therapeutics Performance and Tempest Therapeutics Correlation. Tempest |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tempest Therapeutics. If investors know Tempest will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tempest Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.60) | Return On Assets (0.54) | Return On Equity (2.89) |
The market value of Tempest Therapeutics is measured differently than its book value, which is the value of Tempest that is recorded on the company's balance sheet. Investors also form their own opinion of Tempest Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Tempest Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tempest Therapeutics' market value can be influenced by many factors that don't directly affect Tempest Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tempest Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tempest Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tempest Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Other Stockholder Equity Analysis
Compare Tempest Therapeutics and related stocks such as Indaptus Therapeutics, Rezolute, and Comera Life Sciences Other Stockholder Equity Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INDP | 201 M | 201 M | 201 M | 201 M | 201 M | 201 M | 201 M | 201 M | 201 M | 201 M | 7.7 M | 51.5 M | 54.4 M | 57.4 M | 59.5 M |
| RZLT | 81.7 K | 81.7 K | 3.8 M | 24.1 M | 38.3 M | 53.7 M | 74.8 M | 90.7 M | 128.4 M | 154.6 M | 194.2 M | 358.6 M | 377.5 M | 450.5 M | 473 M |
| FBRX | 133.7 M | 133.7 M | 133.7 M | 133.7 M | 133.7 M | 133.7 M | 137.4 M | 146 M | 274.1 M | (10.3 M) | 110.4 M | 114.7 M | 125.8 M | 153.8 M | 105.4 M |
| SANA | 59 K | 59 K | 59 K | 59 K | 59 K | 59 K | 59 K | 59 K | 59 K | (415.8 M) | (844.7 M) | 385.8 M | 1.6 B | 1.6 B | 1.7 B |
| OLMA | 239 K | 239 K | 239 K | 239 K | 239 K | 239 K | 239 K | 239 K | 239 K | 168 K | 371.2 M | 388.9 M | 408.3 M | 559.2 M | 316.8 M |
| CGEM | 214 K | 214 K | 214 K | 214 K | 214 K | 214 K | 214 K | 214 K | 214 K | (137 M) | (261 M) | 582.3 M | 585.3 M | 654.7 M | 687.4 M |
| ZNTL | 56 K | 56 K | 56 K | 56 K | 56 K | 56 K | 56 K | 56 K | 56 K | 159.7 M | 534.1 M | 724.1 M | 1 B | 1.3 B | 691.8 M |
| LYEL | 18.1 M | 18.1 M | 18.1 M | 18.1 M | 18.1 M | 18.1 M | 18.1 M | 18.1 M | 18.1 M | 18.1 M | 41.4 M | 388.3 M | 1.6 B | 1.7 B | 1.7 B |
| GLUE | 50 K | 50 K | 50 K | 50 K | 50 K | 50 K | 50 K | 50 K | 50 K | 50 K | 336.2 K | 105.2 M | 503.7 M | 547.9 M | 575.2 M |
| RVMD | 2.4 M | 2.4 M | 2.4 M | 2.4 M | 2.4 M | 2.4 M | 2.4 M | 2.4 M | 210 M | 4.7 M | 172.7 M | 317.6 M | 1.4 B | 3 B | 3.1 B |
| RNXT | 235 K | 235 K | 235 K | 235 K | 235 K | 235 K | 235 K | 235 K | 235 K | 235 K | 303 K | 36.6 M | 31.2 M | 38.4 M | 23.5 M |
| IKNA | 5.6 M | 5.6 M | 5.6 M | 5.6 M | 5.6 M | 5.6 M | 5.6 M | 5.6 M | 5.6 M | 5.6 M | 10.3 M | 353.3 M | 361.9 M | 452.1 M | 260.3 M |
| AKTX | 9.9 M | 9.9 M | 13.3 M | 25.7 M | 34.1 M | 87 M | 91 M | 104.8 M | 104.8 M | 122.3 M | 179.6 M | 205.3 M | 219.3 M | 174.8 M | 116.1 M |
| ARMP | 19.5 M | 326.2 M | 332.8 M | 371.2 M | 363.5 M | 375.2 M | 390.9 M | 401.8 M | 414.5 M | 172 M | 198.4 M | 228 M | 275.5 M | 276.4 M | 251.6 M |
| ANEB | 12 K | 12 K | 12 K | 12 K | 12 K | 12 K | 12 K | 12 K | 12 K | 12 K | 60 M | 60.5 M | 67.8 M | 69.2 M | 56.7 M |
| PCSA | 20 K | 3.7 M | 6 M | 8.6 M | 14.3 M | 0.0 | 12.9 M | 12.9 M | 17.3 M | 19 M | 48.3 M | 62.3 M | 71.7 M | 80.4 M | 84.4 M |
Tempest Therapeutics and related stocks such as Indaptus Therapeutics, Rezolute, and Comera Life Sciences Other Stockholder Equity description
My Equities
My Current Equities and Potential Positions
| Tempest Therapeutics | TPST |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Michigan; U.S.A |
| Exchange | NASDAQ Exchange |
USD 1.1
Additional Tools for Tempest Stock Analysis
When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.